Ferentis selected for European Commission‘s SME Instrument Grant

Ferentis‘ BIOTIMA project has been selected by the European Commission in second round of calls, to join the SME Instrument (Phase 1) Horizon 2020 programme of the European Union.  Phase 1 activities will entail development of a market feasibility study and business plan for commercialisation of Ferentis‘ biomimetic tissue matrix.  The project addresses the need for efficient toxicity testing/cell culture tools enabling more physiologically relevant, predictive and functional tissue mimicking models.  The proposal was submitted under the Topic „Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs“.

The SME instrument has been designed for highly innovative SMEs with international ambitions, determined to turn strong, innovative business ideas into winners on the market. The instrument provides full-cycle business innovation support from the stage of business idea conception and planning (phase I) over business plan execution and demonstration (phase II) to commercialisation (phase III). Participants will be able to call on business innovation coaching for the duration of their project.